China Oncology ›› 2021, Vol. 31 ›› Issue (3): 221-226.doi: 10.19401/j.cnki.1007-3639.2021.03.009

• Review • Previous Articles     Next Articles

Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer

HU Xi’e 1 , YANG Zhenyu 1 , XUE Jingyi 2 , YANG Ping 1 , PENG Shujia 1 , YUAN Lijuan 1 , BAO Guoqiang 1   

  1. 1. General Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi’an 710038, Shannxi Province, China; 2. The Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang 712000, Shannxi Province, China

  • Online:2021-03-30 Published:2021-04-01
  • Contact: BAO Guoqiang E-mail: guoqiang@fmmu.edu.cn

Abstract: Triple-negative breast cancer is the most invasive and malignant type of breast cancer. At present, therapy for triple-negative breast cancer is the comprehensive treatment regimens based on chemotherapy, in which neoadjuvant chemotherapy plays an important role. However, nearly half of the patients with triple-negative breast cancer are resistant to the treatment, and the specific mechanism is still unclear. Single-cell sequencing is based on accurate assessment of a single cell of tumor, which can evaluate the changes of genome, transcriptome and epigenetic information of tumor in its occurrence and progression. It provides a powerful tool for the diagnosis of tumor subtypes, understanding the mechanism of drug resistance of tumor, finding new therapeutic targets and evaluating efficacy and prognosis, and has a wide application prospect in the neoadjuvant chemotherapy for triple-negative breast cancer.

Key words: Triple-negative breast cancer, Single-cell sequencing, Neoadjuvant chemotherapy, Tumor heterogeneity